Valvular & structural heart disease
Impact of Recurrent Mitral Regurgitation Following Mitral Transcatheter Edge-to-Edge Repair on Long-Term Outcomes
Main finding · All-cause mortalityResult — go to the resultHazard ratio 1.43 95% CI 1.06–1.93Authors' conclusion
recMR is common and independently associated with increased mortality after M-TEER, with a more pronounced effect in patients with DMR. Identification of patients at risk may inform closer surveillance and timely reintervention.
Study context
- Population
- Patients with mitral regurgitation (MR) undergoing successful mitral transcatheter edge-to-edge repair (M-TEER) (residual mitral regurgitation ≤2+ at discharge) between 2008 and 2021consecutive patients with successful M-TEER · functional mitral regurgitation (FMR) 326 · degenerative mitral regurgitation (DMR) 135
- Participants
- 461 patients
- Exposure
- Patients with recurrent mitral regurgitation (recMR) vs without recMR after successful M-TEER
- recMRn = 146
- Outcome
- All-cause mortality
- Follow-up
- 4 years
Methodological detailsconsecutive patients, 12-month landmark analysis, multivariable Cox regression
- Consecutive patients
- 12-month landmark analysis
- Multivariable Cox regression
Main finding
As reported in the abstract
Hazard ratio
1.43
95% CI 1.06–1.93
P = 0.019
By group
Patients with recMRvs without recMR after successful M-TEER
HR 1.43 (95% CI 1.06–1.93); P = 0.019
Observational data: associations, not effects.
Further findings
Survival, 12-month landmark analysis
- Absence of recMR associated with improved survival (log-rank)
- P = 0.0088
Survival by MR aetiology
- DMR: survival difference significant (log-rank)
- P = 0.014
- FMR: survival difference not significant
- P = 0.11
Incidence of recMR
- recMR overall
- 31.7% (146 of 461)
- recMR among FMR
- 31.9% [104 of 326]
- recMR among DMR
- 31.1% [42 of 135]
- Median follow-up
- 3.44 years (Q1-Q3: 1.51-3.99 years)
Original publication
Impact of Recurrent Mitral Regurgitation Following Mitral Transcatheter Edge-to-Edge Repair on Long-Term Outcomes. JACC Cardiovasc Interv. Published 26 October 2026. doi:10. 1016/ j. jcin. 2026. 07. 015
Composed by AI from the published abstract and checked against it. How Briefs are made →